Transcription from multiple promoters along with alternative mRNA splicing constitutes the basis for cell-specific gene expression and mRNA and protein diversity. The prodynorphin gene (PDYN) gives rise to prodynorphin (PDYN), precursor to dynorphin opioid peptides that regulate diverse physiological functions and are implicated in various neuropsychiatric disorders. Here, we characterized PDYN transcripts and proteins in the adult human brain and studied PDYN processing and intracellular localization in model cell lines. Seven PDYN mRNAs were identified in the human brain; two of the transcripts, FL1 and FL2, encode the full-length PDYN.
cocaine-conditioned place preference (9) . Other animal experiments indicate that dynorphins modulate motor behavior (12) , memory acquisition, and learning (A. Kuzmin, N. Madjid, L. Terenius, S. O. Ogren, and G. Bakalkin, unpublished data) and mediate the dysphoric effects of marijuana (13) . Inhibition of dynorphin expression is also associated with antidepressant-like properties (14, 15) . There is also indirect evidence for the importance of the prodynorphin system in human psychopathology. Salvinorin A, the most potent naturally occurring hallucinogen, has been recently identified as a ligand for κ-opioid receptors, suggesting that the dynorphin/κ-opioid system is involved in perceptual impairments in schizophrenia, bipolar disorder, and Alzheimer's disease (16) . Altered expression of PDYN has been observed in the brain of drug abusers and psychiatric patients (17, 18) and allelic variations in the PDYN promoter appear to be associated with cocaine abuse and epilepsy (19, 20) .
Multiple promoters and alternative mRNA splicing, general mechanisms to regulate cell-and tissue-specific gene expression and to increase mRNA and protein diversity may be relevant for differential expression of genes such as PDYN in the central nervous system (CNS) with regard to cellular localization and high levels of plasticity in adaptive responses. The canonical form of PDYN pre-mRNA consisting of three introns (A, B and C) and four exons coding for the fulllength protein (FL1-PDYN mRNA) has been identified in the adult human brain (21, 22) . Promoter elements controlling transcription of this mRNA have been studied (23-25). We previously detected alternative human PDYN transcripts coding the FL protein in the embryonic human brain (FL2), testis (Taf1 and Taf2) and 5′-truncated transcripts initiated in exon 4 in embryonic brain (22) . Other than FL1, little is known about PDYN transcripts, their promoters and protein products in the adult human brain that might provide eventual insight into the role of the PDYN system in neuropsychiatric disorders. As such, a detailed characterization of PDYN mRNAs and proteins in the adult human brain was undertaken in the present study.
MATERIALS AND METHODS

RNA preparations, PCR, 5′-end identification
Total RNA from human brain was obtained from Ambion (Austin, TX). Total RNA from human caudate nucleus and hippocampus was isolated with the guanidine isothiocyanate method (26). In the first set of experiments the rapid amplification of cDNA ends procedure (RACE) based on dA-tailed cDNA (27) was used for identification of 5′-ends of PDYN mRNAs.
FL1-and FL2-PDYN mRNAs have different first exons: exon 1 and exon 2´, which is initiated in intron A (Fig. 1 ). FL1 and FL2 mRNAs were reverse-transcribed with the same antisense primer PDYN212R (5′-CCAGGCCATCCTGTCTCAGCAATT-3′, number in primer name corresponds to 3′ positions of primer on PDYN mRNA, accession number NM_024411). To determine 5′-ends of FL1-and FL2-PDYN mRNAs, the first PCR was performed with antisense PDYN212R primer and sense A1-pT primer 5′-CCTACTACGACTCACGGATCCTA(T) 19 -3′, which annealed to poly(dA)-tail. Nested PCR was performed with sense A1 and antisense primers specific for the first exons of FL-mRNAs: for exon 1 of FL1-mRNA primer PDYNE1a 5′-ACCTGCACTCTGCTTTGTCCCT-3′ used in the first round, and primer PDYNE1b 5′-TAGAACAAAGGCAAGGTGTGGT-3′ in the second round and for exon 2´ of FL2-mRNA primer PDYNE2a 5′-GCCTTTGCACTTTCTGTTCTTCT-3′, used in the first round and primer PDYNE2b 5′-GGAAAAGAGAAGGAAGGTGCCA-3′ in the second round.
Alternative splicing form Sp1 was detected when PDYN mRNA was reverse-transcribed with antisense primer PDYN994R 5′-GCACAAGCTTCTCTACTCCATGAAAAGAGGT-3′ and subjected to PCR with PDYN994R and sense PDYN246F 5′-GGATGGCCTGGCAGGGGCTGGT-3′ primers followed by a second round of amplification with antisense PDYN895R 5′-GAGAAAACCGCCATAGCGCTTC-3′ and sense PDYN348F 5′-AGGATGGTCCCAAACCTATCAA-3′ primers.
Truncated forms Ts were identified when PDYN mRNA was reverse-transcribed with antisense primers PDYN1086R 5′-GTACACAATGCTGAGCTGAGCAT-3′, PDYN994R and PDYN731R 5′-CCATAGCGTTTGACCTGCTCCTT-3δ′. PCR amplification was performed with antisense primers used to generate cDNA and sense primer A1. Nested PCR was performed with antisense primers PDYN1038R, 5′-TGAATGAATGCACTCCAACCTGAA-3′, PDYN926R, 5′-TCCTGAGACCGAGTCACCACCTTGAA-3′, PDYN706R, 5′-GGTCCTCCTCAGCGAGATAGAGT-3′, and sense primer A1.
In the second set of experiments human brain RACE-ready cDNA kit (Ambion) was used for identification of 5′-capped PDYN mRNAs with a synthetic RNA adaptor oligonucleotide ligated by RNA-ligase to the 5′-end of triple oligo (dT) selected mRNAs according to RNA-ligasemediated RACE procedure (RLM-RACE).
To determine 5′-ends of FL1-and FL2-PDYN mRNAs, the first PCR was performed with 5′ RACE outer primer (Ambion) and PDYN212R primer. Nested PCR for FL1-mRNA was performed with 5′ RACE inner primer (Ambion) and PDYNE1a primer. Nested PCR for FL2-mRNA was performed with 5′ RACE inner primer and PDYNE2a primer for the first round of amplification and PDYNE2b primer for the second round.
Other PDYN transcripts, including Sp2, were found when human brain RACE-ready cDNA was amplified with 5′ RACE outer primer and one of the PDYN731R, PDYN994R, or PDYN1086R primers, followed by nested PCR with 5′ RACE inner primer and one of the PDYN706R, PDYN926R, or PDYN1038R primers. Resulting PCR products generated by both methods were gel-purified and directly sequenced.
Plasmid construction
PDYN cDNAs coding FL-, Sp1-, T1-and T2-PDYNs were generated by PCR with specific primers using cDNA from human hippocampus and nucleus accumbens and cloned into BglII/HindIII sites of pCMV4 plasmid to construct pCMV-h-FL-PDYN, pCMV-h-Sp1-PDYN, pCMV-h-T1-PDYN, and pCMV-h-T2-PDYN plasmids, respectively.
The exon 4 fragment (location 129/761; Fig. 1 ) that covers 5′-ends of both T1-and T2-transcripts ( Fig. 1 ) was generated by PCR using pCMV-h-FL-PDYN plasmid and inserted upstream the enhanced green fluorescent protein (EGFP) coding sequence into pEGFPN1 plasmid (Clontech, San Diego, CA, USA), from which the CMV promoter was excised as an AseI-BamHI fragment, giving rise to pEx4-EGFPN1 plasmid. Promoterless AseI-BamHI fragment of pEGFPN1 plasmid was also treated with Klenow fragment and ligated to create pEGFPN1(-CMV) plasmid.
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First exon of FL1 (exon 1; -217/-72) transcript and fragment of FL2 exon 2´ (exon 2´; -254/-88) lacking exon 2 sequence were inserted into HindIII-EcoRI sites of the pEGFPN1 vector between CMV promoter and sequence encoding EGFP yielding pEGFP-FL1 and pEGFP-FL2 plasmids. PCR products used for cloning were sequenced in both directions.
Prodynorphin in situ hybridization histochemistry (ISHH)
cDNAs templates for riboprobes used for ISHH corresponded to 5′-regions of the FL1-and FL2-PDYN and exon 4-mRNAs (location -215/-72, -251/-88 and 566/724, respectively; Fig. 1 ). They were inserted into HindIII-EcoRI sites of the pGEM3Z plasmid and antisense and sense riboprobes were generated by in vitro transcription using SP6 and T7 polymerase, respectively, and [
35 S]-UTP (New England Nuclear, Boston, MA). ISHH was carried out on fresh-frozen (dry ice-cooled) human brain sections containing striatum, hippocampus, or amygdala obtained at autopsy, according to approved ethical guidelines from the Karolinska Institute. The subjects were four males and two females with a postmortem interval of 15.4 ± 3.1 h, 42.5 ± 4.9 years old, and the cause of death was acute cardiovascular failure. ISHH was carried out under established conditions for studying PDYN mRNA expression levels in the primate brain (18, 28) . Briefly, the labeled riboprobe was added to the hybridization cocktail in a concentration of 20 × 10 3 cpm per μl, and 0.2 ml of this hybridization mixture was applied to prefixed brain sections (20 μm-thick). Hybridization was carried out overnight at 55°C in a humidified chamber (higher stringency hybridization experiments were also carried out at 65°C). After the hybridization procedure, the slides were exposed to Hyperfilm (Amersham, Buckinghamshire, England) for a period of 3-5 weeks. Six striatal brain specimens from midgestational (approximately week 20 of development) human fetuses (see details in Ref. 29) were also processed using the same ISHH procedure.
Cell/tissue extracts
Extracts were prepared as described elsewhere (30, 31) . Buffers were supplemented with 5 × protease (Complete, Roche Diagnostics GmbH, Mannheim, Germany) and proteasome (5 µM MG132; Affinity, Exeter, UK) inhibitors. Tissues were also homogenized in Triton X-100 lysis buffer (10 mM Tris-HCl, pH 8.0, 1% Triton X-100), and insoluble material collected by centrifugation at 20,000 g for 10 min was solubilized in SDS buffer (0.45 M Tris-HCl, pH 8.5, 2.5% glycerol, and 4% SDS), boiled for 5 min and DNA was sheared by ultrasonication. Protein concentration was determined with the Micro BCA TM (Pierce, Rockford, IL) or Bio-Rad (BioRad Laboratories, Hercules, CA) protein assay. Extracts of cells expressing truncated PDYN proteins were mixed with trifluoroacetic acid (TFA; 0.1% final), loaded on C 18 -SEP-PAC columns (Waters Inc., Milford, MA) and eluted with 97% acetonitrile/3% TFA.
Anti-human PDYN antibodies and Western blot analysis
Rabbit polyclonal antisera were generated against human PDYN C-terminal fragment (CTF241-254), conjugated with keyhole limpet hemocyanin via Cys added to its N terminus. IgG fractions were purified with Protein A-Sepharose. These antibodies recognized all PDYN variants identified in the present study because these proteins contain the same C terminus. Anti-GFPantibodies were obtained from Roche Diagnostics. Aliquots of cell/tissue extracts were prepared under reducing conditions: samples were heated for 5 min at 95°C in the presence of 5 mM β-mercaptoethanol and resolved by SDS-PAGE on 10% or 16% Tricine precast gels (Novex/Invitrogen, Carlsbad, CA). Proteins were transferred at 4°C onto a nitrocellulose membrane (Schleicher and Schuell, Dassel, Germany), which was blocked in 5% nonfat dry milk, incubated with antibodies, and developed with the ECL detection system (Amersham, Little Chalfont, UK).
Cell culture, transfection, and immunocytochemistry COS1, SH-SY5Y cells, and RINm-5F cells cultured in Iscove's or RPMI medium with 10% fetal calf serum were transfected with plasmid DNA and lipofectamine (Invitrogen, Carslbad, CA). 
Radioimmunoassay
The procedure was described elsewhere (32) . Cell culture medium mixed with acetic acid (1 M final) was diluted with TFA (1% final), loaded on C 18 -SEP-PAC columns and dynorphins were eluted with the 60% acetonitrile/1% TFA. Lyophilizates and tissue/cell extracts were run through SP-Sephadex ion exchange C-25 columns, and dynorphins were analyzed by RIA.
RESULTS
PDYN mRNA variants in the adult human brain
Two approaches were used to characterize in detail PDYN transcripts in the adult human braina conventional method of poly(dA)-based RACE, which detects all mRNAs and RLM-RACE, which selectively detects 5′-capped mRNAs. We identified four forms of PDYN mRNAs including FL1 (two initiation sites), FL2 (three initiation sites), and 5′-truncated T1 and T2 transcripts initiated within exon 4 in RNA samples prepared from adult human brain by both methods (Fig. 1A) . One truncated transcript T3 initiated within exon 4 at the stop codon was found only by poly(dA) RACE.
Two FL1 transcripts in the brain are initiated 11 and 16 nt (positions -217 and -222, respectively, Fig. 1 ) upstream of the transcription initiation sites identified in the same tissue by the Marathon cDNA amplification assay (22) . The FL2 transcript has a novel exon 2´ that includes exon 2 and is initiated at three sites located within intron A 64, 29, and 21 nt upstream of the site previously detected in the embryonic brain (22) . The 5′-truncated PDYN transcripts T1 and T2 are initiated within the coding part of exon 4 (T1; one initiation site, T2; two initiation sites), whereas T3 is initiated at the stop codon (one initiation site). T1 and T2 give rise to PDYN peptides initiated at Met146 and Met198, respectively. Both RACE methods failed to detect testis-specific Taf1-and Taf2-PDYN mRNAs in the adult human brain tissue.
In the course of characterizing PDYN cDNA by poly(dA) RACE, two PCR products were identified after the second round of amplification of hippocampal mRNA using 5′-and 3′-ends PDYN-specific primers. Sequence analysis of these products showed that the longer fragment corresponds to FL1-PDYN mRNA, whereas the shorter fragment represents a novel splice variant of the PDYN mRNA (Sp1) that lacks 363 nt of exon 4 and contains canonical splice signals around donor and acceptor splicing sites (Fig. 1B) . Alternative splicing at these sites would result in an "in frame" translation of the 133 aa PDYN (Sp1) that retains the signal peptide and opioid peptide sequences but lacks the 51-171 aa central segment of the molecule.
The new PDYN splice variant Sp2 was identified by RLM-RACE (Fig. 1) . Sp2 consists of two exons 1a and 4c and intron E. Exon 1a is initiated 146 nt upstream of the exon 1 (initiation site at -217) and includes the 5′-part of exon 1. Exon 4c includes the 3′-part of exon 4 and contains the three dynorphin-encoding sequences. Sp2 may be translated into the T1 protein.
Differential expression pattern of the full-length PDYN mRNAs in the human brain
The pattern of PDYN gene expression in human brain was studied using in situ hybridization histochemistry (ISHH) with two riboprobes specific for the 5′-end of the FL1-and FL2-PDYN mRNAs and with a third riboprobe for exon 4 ( Fig. 1) , which should recognize both FL-and T-PDYN mRNAs. The use of the antisense probes resulted in specific hybridization signals with some individual variability in regard to the magnitude, but not the pattern, of the expression levels of the PDYN transcripts; no sex or age differences could be discerned due to the small sample size. The same patterns were obtained even when the hybridization stringency conditions were increased. In contrast, brain sections hybridized with the sense riboprobes failed to produce hybridization signals above background levels (data not shown). High levels of the FL1 transcript were detected in the adult human striatum (nucleus accumbens and patch (striosome) compartment of the caudate nucleus and putamen), accessory basal amygdala, periamygdala cortex, cortical amygdala nucleus, lateral division of the basal nucleus of Meynert, dentate gyrus of the hippocampus, and entorhinal cortex ( Fig. 2; left panel) . Low-to moderate-FL1-mRNA expression levels were also detected in the lateral amygdala and lateral hypothalamus. FL2-mRNA was more limited in distribution with expression predominantly localized to the claustrum, medial subdivision of the basal nucleus of Meynert, supraoptic hypothalamic nucleus, and lateral division of the central amygdala nucleus (Fig. 2; center panel) . The exon 4 probe resulted in a hybridization pattern that was generally a combination of the structures that expressed the FL1 and FL2 transcripts.
The two PDYN transcripts were found in the midgestational human fetal brain (Fig. 2B) . Similar to the pattern observed in the adult human brain, the expression of the FL1 mRNA was predominantly localized to the striatal patches. The FL2 riboprobe resulted in a homogenous signal in the striatum. detect PDYN rabbit polyclonal antibodies against human PDYN, C-terminal fragment (CTF241-254) were generated and characterized by Western blotting (Fig. 3A) . The antibodies detected a single band in COS1 cells transfected with pCMV-h-FL-PDYN plasmid but not with vector plasmid (Fig. 3A, lanes 1 and 2) . The apparent 28-kDa protein molecular size was identical to the calculated size of FL-PDYN. The signal was blocked by preincubation of antibodies with 10 nM h-CTF (Fig. 3A, lanes 3 and 4) , whereas the corresponding rat PDYN CTF, differing in sequence from the human counterpart did not interfere with labeling (Fig. 3A, lanes 1 and 2) . High levels of the FL-PDYN were detected in the nucleus accumbens, whereas the signal was weaker in the amygdala and virtually absent in the cerebellum (Fig. 3B, lanes 2-7) . A substantial fraction, 30 to 50% of FL-PDYN was extracted from brain tissues with 1% Triton X100-buffer (Fig. 3B,  lanes 3 and 4) . Additional FL-PDYN was detected in a SDS-soluble fraction (Fig. 3B, lanes 6  and 7) . This supports the notion that a fraction of FL-PDYN is present in the brain in the form of Triton X-100 insoluble protein aggregates (unpublished observations). Thus, PDYN is not immediately processed into opioid peptides, but is stored in or transported through the secretory pathways as the FL-protein.
Translation of FL1 and FL2 PDYN mRNAs and processing of their protein products
To test whether FL1-and FL2-mRNAs are functional, their peptide products were analyzed in the caudate nucleus and claustrum (Fig. 4) . The relative expression level of FL1 in the caudate nucleus exceeded that of FL2 in the claustrum approximately twofold (Fig. 4A) . Consistently, PDYN and its processing product dynorphin B were detected in both structures with twofold higher levels in the caudate nucleus compared with the claustrum (Fig. 4B-D) . Thus both FL1 and FL2 mRNAs are translated into PDYN, which is apparently processed into opioid peptides in both brain regions.
Regulatory functions of the first FL1 and FL2 exons
To test whether exon 1 of FL1 transcript and part of exon 2´ sequence that is specific for the FL2 transcript (see Fig. 1 ) are involved in the regulation of the PDYN gene expression, these sequences were inserted into a pEGFPN1 plasmid between a CMV promoter and the protein coding sequence. The plasmids were transfected into human neuroblastoma SH-SY5Y cells, and the expression of the EGFP reporter gene was analyzed (Fig. 5 ). Western blotting with anti-EGFP-antibodies demonstrated that insertion of the FL1 exon 1 results in a twofold increase in EGFP expression (Fig. 5, lane 2) . Strong, 10-fold inhibition of expression was observed when the FL2 exon 2´ fragment was incorporated (Fig. 5, lane 3) . Thus expression of FL1-and FL2-mRNAs may be regulated through exons 1 and 2´.
Translation of Sp1 PDYN mRNA and processing of its protein product
The splice variant Sp1 of PDYN mRNA lacking 363 nt in the coding part of exon 4 may generate a truncated 133 amino acid protein that retains a signal peptide and the opioid peptide sequences. To test whether Sp1 mRNA is translated and the Sp1 protein is processed into peptides, Sp1 cDNA under control of the CMV promoter (pCMV-h-Sp1-PDYN) was transfected into rat insulinoma RINm-5F cells. Protein and peptide products were analyzed by Western blotting with anti-h-PDYN C-terminal peptide antibodies and by RIA for dynorphin B (Fig. 6 ) and dynorphin A (not shown). RINm-5F cells were chosen since they do not express endogenous PDYN and efficiently process ectopic FL-PDYN into opioid peptides (unpublished observations).
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Measurements of dynorphin levels in extracts of RINm-5F cells transfected with pCMV-h-Sp1-PDYN plasmid demonstrated that Sp1-mRNA is translated into a protein product that is processed into dynorphin B (Fig. 6B ) and dynorphin A (data not shown), and that these peptides are secreted into the culture medium. Efficiency of generation of opioid peptides from Sp1 protein is, however, approximately fourfold lower than that of FL-PDYN, suggesting a critical role of the deleted segment in the processing of FL1 precursor. Low levels of PDYN with molecular size 16 kDa that coincide with the calculated size of Sp1-PDYN generated from the pCMV-h-Sp1-PDYN plasmid were identified by Western blotting (Fig. 6C) , suggesting rapid processing of this protein into dynorphins.
Truncated PDYN proteins
To test whether truncated PDYN mRNA can be translated, T1-and T2-PDYN cDNAs under control of the CMV promoter were transfected into COS1 cells. Peptide fractions isolated from cell extracts were separated on C 18 -SEP-PAK columns and analyzed by Western blotting with anti-h-PDYN CTF antibodies (Fig. 7A ). COS1 cells were chosen for analysis because they express proteins from CMV plasmids at very high levels. Bands with apparent molecular size of 12 and 6 kDa, respectively, coinciding with the calculated molecular size of T1-and T2-PDYN, were detected in cells transfected with expression plasmids but not with vector plasmid (Fig. 7A) . The T1-and T2-PDYN levels were much lower than that of FL-PDYN expressed from the same CMV promoter, suggesting low efficiency of translation of T1-and T2-mRNAs or rapid degradation of the mRNAs or protein products. COS1 cells transfected with CMV-h-FL-, CMVh-T1-, and CMV-h-T2-PDYN plasmids were labeled with anti-h-PDYN CTF antibodies to characterize PDYN localization in cells. FL-PDYN demonstrated a pattern characteristic for localization in the endoplasmic reticulum (Fig. 7B ). T1-PDYN was primarily localized in the cell nuclei, whereas the T2 protein was seen exclusively in the cytoplasm of transfected cells. This indicates that the nuclear localization signal is situated between the Met146 and Met198 residues in the N-terminal segment of the T1-PDYN that is absent in T2-PDYN. Consistently, a bipartite nuclear localization signal, which includes the α-neoendorphin sequence is predicted at the N terminus of human and rat T1-PDYN (Fig. 7C) by the PSORT II program.
Promoter activity of exon 4
Transcription of the T1-T3 PDYN mRNAs may be initiated by an intragenic promoter located in exon 4 and adjacent sequences. Promoter activity of exon 4 was tested with pEx4-EGFPN1 plasmid containing exon 4 located upstream of the EGFP gene in a promoterless construct. Analysis of the exon 4 promoter activity was restricted to COS1 cells because several other neuronal and non-neuronal cell lines produced low levels of GFP from pEx4-EGFPN1 plasmid. Approximately 10% of the cells demonstrated bright EGFP fluorescence when COS1 cells were transfected with pEGFPN1 plasmid as a positive control (Fig. 8) . Bright fluorescent cells were observed in cultures transfected with pEx4-EGFPN1 plasmid, but not with promoterless pEGFPN1(-CMV) plasmid. A number of such bright cells was 10 4 -lower compared with pEGFPN1-transfected cultures. Thus, exon 4 has promoter activity that may contribute to the intragenic initiation of transcription of truncated PDYN mRNA.
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DISCUSSION
Our study demonstrates that the PDYN gene has a complex pattern of transcription in the adult human brain, in which seven mRNA with different 5′-ends were detected. In cell lines, the transcripts were translated into four proteins located either in the endoplasmic reticulum, nucleus, or cytosol, suggesting different cellular functions. The two FL transcripts were translated into FL-PDYN and processed into dynorphins in the brain. A marked difference in the regional distribution pattern of the two FL-PDYN transcripts was observed throughout the human brain, suggesting distinct involvement of the FL1 and FL2 transcripts in motor, reward, memory, and endocrine functions. The first exon was critical for differential regulation of these transcripts and may control regional specificity of their expression. The complex regulation of PDYN expression currently revealed in the human brain may be associated with its discrete neuroanatomical organization and high levels of plasticity in adaptive responses.
Altogether, nine human PDYN transcripts -FL1, FL2, Taf1, Taf2, Sp1, Sp2 T1, T2 and T3 -are described in our previous (22) and present study. Northern blot analysis demonstrated the presence of the major 2.8 kb PDYN transcripts and two minor 2.3 kb and 3.2 kb PDYN mRNAs in the adult human brain (22) . One of the 2.8 kb mRNAs was previously identified as FL1-transcript. Six other PDYN transcripts FL2, Sp1, Sp2, and T1-T3 were found in the adult human brain in the present study (see Fig. 1 ). Novel initiation sites were detected for the FL1 (two sites) and FL2 (three sites) transcripts; these sites and also the Sp2 initiation site are located upstream of those previously identified in the adult and fetal brain (22) . T1-and T2-transcripts were identified using both poly(dA) selected mRNAs and by the RLM-RACE that detects 5′-capped molecules, which suggests that these mRNAs are functional and translated into proteins. FL2-and Ts-PDYN mRNAs apparently correspond to the 2.8 kb and 2.3 kb transcripts, respectively.
In regard to the FL-PDYN transcripts, a marked difference in the regional distribution pattern was observed throughout the human brain, suggesting different functions for the FL1 and FL2 mRNAs. The FL1 is highly expressed as compared with the FL2 and shows a classic PDYN mRNA distribution pattern with labeling predominantly in limbic-related structures of the human brain, such as the nucleus accumbens, hippocampus, amygdala, patch compartment of the dorsal striatum, and entorhinal cortex. Because of the higher abundance of the FL1-mRNA compared with FL2-mRNA, the FL1 distribution pattern was similar to that observed with the exon 4 probe in our previous (18) and present studies. On the basis of the anatomical organization, it would be expected that the FL1-derived peptides are involved in, e.g., reward, motivation, motor function, learning and memory, and emotional expression. Only few brain areas such as the claustrum express the FL2 transcript. The claustrum is known to have reciprocal connectivity with various cortices such as the occipital, as well as prefrontal, cingulate, and motor areas, in addition to the basolateral amygdala (33) . Thus the claustrum should be important for integration of information related to sensory, motor, and limbic processes. Even when present in the same brain structure, the two PDYN mRNA forms were specifically localized to discrete subnuclei. For example, in the hypothalamus the FL1-mRNA was present in the lateral nucleus, suggesting that the FL1-derived peptides would be involved in, e.g., feeding and the regulation of sleep. The FL2-transcript was instead more prominent in the supraoptic nucleus where the dendritic release of dynorphins is known to regulate neurosecretion of oxytocin and vasopressin (34, 35) . Both PDYN transcripts were apparent in the basal nucleus of Meynert, but the FL1-form was predominantly expressed in the lateral subdivision, whereas the FL2-mRNA was expressed in the medial subdivision of this cell group. The FLs are also expressed in the midgestational
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human fetal brain, where they are processed into dynorphins (unpublished data). This observation suggests a role of dynorphins in synaptic transmission at the early stages of development of the CNS. The brain region-specific distribution of FL1-and FL2-PDYN mRNAs suggests that their expression is controlled by different promoters. Several promoter elements relevant for initiating FL1 transcription have been identified, including the noncanonical AP-1 binding site activated by phorbol ester (3, 23) . The basal and protein kinase A (PKA)-activated expression of FL1-PDYN mRNA is critically regulated through the downstream regulatory element (DRE) in the 5′-untranslated/exon 1 region by DREAM, the DRE antagonistic modulator (24, 25). Here, we found that FL1 exon 1 activates and the FL2 exon 2´ inhibits expression of a reporter gene, respectively, suggesting that their functions are associated with regulation of PDYN synthesis. These exons may contain different cis-regulatory elements targeted by trans-acting factors that may differentially control the region specificity of PDYN expression in human brain.
The presence of dynorphins is well documented in the human brain (36) and cerebrospinal fluid (37) , suggesting that these peptides are processed from PDYN and then released from neurons. Our detection of FL-PDYN, derived apparently from the FL transcripts, now provides the first evidence that dynorphins are processed from the FL-precursor in the human brain. Similar to the FL transcript, the spliced Sp1 PDYN mRNA is expected to produce Sp-1 PDYN that retains the signal peptide and the opioid peptide sequences, but lacks almost half of the FL-protein. Indeed, the Sp1 transcript generated the 16 kDa PDYN that was processed into dynorphins in RINm-5F cells. Processing apparently occurs in the secretory pathway because dynorphins are secreted into culture medium. The levels of Sp1 and FL PDYNs, as well as dynorphins differ substantially, which suggests differential regulation of intracellular trafficking and processing of these precursor proteins.
Another novel observation in the adult human brain was the identification of the three new 5′-truncated T1-T3 transcripts that can be generated from the intragenic promoter located in exon 4. Experiments with exon 4-EGFP reporter plasmid demonstrated that this exon has a promoter activity that may contribute to the initiation of transcription of the T transcripts. The presence of cap on the 5′-end of truncated transcripts supports the notion of initiation of transcription within exon 4. Although no TATA box-like sequences appear to be present in the exon 4, binding sites for the multifunctional transcription factor YY1 have been identified in exon 4 (31, 38) . YY1 interacts directly with RNA polymerase II and initiates transcription from the TATA-less promoters (39) . Several κB elements are present in exon 4, suggesting NF-κB-dependent regulation of transcription of T-PDYN mRNAs (30) . DNA binding sites for YY1 and other factors have been found within coding regions of several genes (40) (41) (42) , so the potential for such regulation would not be unique for PDYN.
The T-PDYN transcripts are capable of being translated to proteins. The longest open-reading frames in PDYN transcripts initiated in exon 4 give rise to T1-and T2-PDYN proteins. According to the Kozak's rules (43) , two AUG codons in these open-reading frames coding for Met146 and Met198 are relatively strong initiators of translation and appear to initiate translation of T1-and T2-PDYNs, respectively. The levels of expression of the T1-and T2-PDYNs in COS1 cells were much lower then those of FL-PDYN transcribed from the same CMV promoter, suggesting low stability of T-PDYN mRNAs or T-proteins. Examination of the T1-PDYN aa sequence identified a bipartite nucleus localization signal that overlaps with the α-neoendorphin sequence and apparently targets the T1-protein to the nucleus. This signal is absent in T2-PDYN, and the protein resides in the cytosol. Nucleotide and amino acid sequences of opioid peptide precursors display a similarity with several eukaryotic transcription factors lil-1 and twist (44) . Consistent to the current observations for PDYN, the proopiomelanocortin (POMC) gene generates, apart from the transcript coding a FL protein, 5′-end truncated mRNA translated into N-terminally truncated POMC proteins, which lack a signal peptide and do not enter the endoplasmic reticulum (45) . In addition, proenkephalin is found not only in the endoplasmic reticulum but also in the cell nucleus and its expression correlates with cell proliferation (46) . The nuclear localization and sequence similarity with DNA binding factors suggest a novel, nonopioid function for T1-PDYN.
It is important to note that the processing of PDYN and subcellular localization of the truncated PDYNs were only examined in cell lines due to the technical challenges of carrying out such studies directly in the human brain. Nevertheless, the findings should be relevant, since the cell lines possess the basic cellular mechanisms for protein trafficking and processing that are present in the brain.
In summary, this study highlights the complex organization of the human PDYN gene. In contrast to human, only one or two PDYN transcripts, which code for the FL-proteins, have been identified in the rodent, guinea pig, lungfish, and amphibia (47) (48) (49) (50) . Most exons are strongly conserved in the human, mouse, and rat genomes. However, exons that are only included in minor alternative splice forms (as opposed to the constitutive or major transcript form) are frequently characterized by their recent creation (51) . The expression of minor human PDYN mRNA forms that are either spliced (Sp1, Sp2) or contain new exons (FL2, Taf1, Taf2) and that are apparently absent in other species, supports the notion of an association of alternative splicing in the human genome with recent evolutionary changes. Whether impairment of the complex PDYN regulatory mechanisms at the levels of gene transcription and translation may ultimately define human pathological conditions, including chronic pain, neurodegenerative diseases, substance dependence, depression, and epilepsy is an important topic for future studies. 
